Register for our free email digests:
Latest From Allakos Inc.
The San Diego start-up will use its Series A round to continue development on a pair of drugs for cholestatic liver disease. Once studied by Pfizer and Sanofi to fight high cholesterol but shelved years ago as statins proved more effective, the drugs show promise in orphan indications.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings of Start-Ups column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Pharmaceuticals, and Medical Devices sectors.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- Allakos Inc.
- Senior Management
Christopher Bebbington, CEO
Nenad Tomasevic, PhD, VP, Research
- Contact Info
San Mateo, CA
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.